StockData
NovoCure Ltd logo

NovoCure Ltd (NVCR) stock

NVCRNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 9/3033% below fair value
$10.73−0.41 (-3.68%)

Close on Nov 18, 2026Market cap $1.25BP/E –Yield –

NovoCure operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

NovoCure's operating cash flow for the twelve months ending Sep 30, 2026 was -$722.00K. For fiscal 2025 it was -$49.03M. The highest annual figure on record is $99.15M in fiscal 2020.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$49.03M–
FY2024Dec 31, 2024-$26.37M–
FY2023Dec 31, 2023-$73.34M-338.2%
FY2022Dec 31, 2022$30.79M-62.8%
FY2021Dec 31, 2021$82.76M-16.5%
FY2020Dec 31, 2020$99.15M+272.5%
FY2019Dec 31, 2019$26.62M–
FY2018Dec 31, 2018-$1.87M–
FY2017Dec 31, 2017-$33.13M–
FY2016Dec 31, 2016-$107.59M–
FY2015Dec 31, 2015-$99.88M–
FY2014Dec 31, 2014-$74.24M–
FY2013Dec 31, 2013-$52.72M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$22.67M+10.2%
Q2 FY2026Jun 30, 2026$8.13M–
Q1 FY2026Mar 31, 2026-$13.52M–
Q4 FY2025Dec 31, 2025-$18.00M–
Q3 FY2025Sep 30, 2025$20.57M+98.3%
Q2 FY2025Jun 30, 2025-$15.94M–
Q1 FY2025Mar 31, 2025-$35.67M–
Q4 FY2024Dec 31, 2024-$3.45M–
Q3 FY2024Sep 30, 2024$10.38M–
Q2 FY2024Jun 30, 2024-$1.72M–
Q1 FY2024Mar 31, 2024-$31.57M–
Q4 FY2023Dec 31, 2023-$14.56M–
Q3 FY2023Sep 30, 2023-$19.31M-186.1%
Q2 FY2023Jun 30, 2023-$22.74M-244.3%
Q1 FY2023Mar 31, 2023-$16.73M–
Q4 FY2022Dec 31, 2022-$3.71M-125.7%
Q3 FY2022Sep 30, 2022$22.42M-8.1%
Q2 FY2022Jun 30, 2022$15.76M-39.8%
Q1 FY2022Mar 31, 2022-$3.69M-120.7%
Q4 FY2021Dec 31, 2021$14.40M-73.1%
Q3 FY2021Sep 30, 2021$24.40M-21.2%
Q2 FY2021Jun 30, 2021$26.17M+105.4%
Q1 FY2021Mar 31, 2021$17.78M+808.5%
Q4 FY2020Dec 31, 2020$53.48M+668.2%
Q3 FY2020Sep 30, 2020$30.97M+107.7%
Q2 FY2020Jun 30, 2020$12.74M+40.5%
Q1 FY2020Mar 31, 2020$1.96M–
Q4 FY2019Dec 31, 2019$6.96M-58.6%
Q3 FY2019Sep 30, 2019$14.91M+164.4%
Q2 FY2019Jun 30, 2019$9.07M–
Q1 FY2019Mar 31, 2019-$4.32M–
Q4 FY2018Dec 31, 2018$16.81M–
Q3 FY2018Sep 30, 2018$5.64M+121.4%
Q2 FY2018Jun 30, 2018-$7.49M–
Q1 FY2018Mar 31, 2018-$16.82M–
Q4 FY2017Dec 31, 2017-$2.90M–
Q3 FY2017Sep 30, 2017$2.55M–
Q2 FY2017Jun 30, 2017-$5.88M–
Q1 FY2017Mar 31, 2017-$26.91M–
Q4 FY2016Dec 31, 2016-$13.73M–

More NovoCure figures

See a number that looks wrong?